These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 24105676)

  • 1. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.
    Peng H; Liu J; Yang M; Tong S; Yin W; Tang H; Hu P; Hu H; Ren H
    J Clin Pharmacol; 2014 Feb; 54(2):189-200. PubMed ID: 24105676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. De novo combined lamivudine and adefovir dipivoxil therapy vs entecavir monotherapy for hepatitis B virus-related decompensated cirrhosis.
    Lian JS; Zeng LY; Chen JY; Jia HY; Zhang YM; Xiang DR; Yu L; Hu JH; Lu YF; Zheng L; Li LJ; Yang YD
    World J Gastroenterol; 2013 Oct; 19(37):6278-83. PubMed ID: 24115827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Observation of combined/optimized therapy of Lamivudine and Adefovir Dipivoxyl for hepatitis B-induced decompensated cirrhosis with baseline HBV DNA>1,000 IU/mL.
    Zhang D; Zhao G; Li L; Li Z
    Acta Gastroenterol Belg; 2017; 80(1):9-13. PubMed ID: 29364091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Entecavir 1.0mg monotherapy or entecavir plus adefovir dipivoxil for patients with lamivudine-resistant chronic hepatitis B had suboptimal response to lamivudine plus adefovir dipivoxil].
    Xing J; Han T; Liu L; Li Y; Li J; Li Y; Xiao SX
    Zhonghua Gan Zang Bing Za Zhi; 2011 Nov; 19(11):828-32. PubMed ID: 22433304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC; He LL; Chen Q
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone.
    Shim JH; Suh DJ; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS
    Hepatology; 2009 Oct; 50(4):1064-71. PubMed ID: 19637288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
    Lai XJ; Lian JS; Chen JY; Zhang YM; Jia HY; Zheng L; Yang YD
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):113-118. PubMed ID: 29804377
    [No Abstract]   [Full Text] [Related]  

  • 10. Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis.
    Zeng T; Xu H; Liu JY; Lei Y; Zhong S; Zhou Z
    J Clin Pharmacol; 2014 Sep; 54(9):959-67. PubMed ID: 24964070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
    Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis.
    Singal AK; Fontana RJ
    Aliment Pharmacol Ther; 2012 Mar; 35(6):674-89. PubMed ID: 22257108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis.
    Lv GC; Yao JM; Yang YD; Zheng L; Sheng JF; Chen Y; Li LJ
    World J Gastroenterol; 2013 Jun; 19(22):3481-6. PubMed ID: 23801842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg-positive chronic hepatitis B patients with resistance to adefovir dipivoxil.
    Lu JJ; Liu K; Ma YJ; Wang J; Chen EQ; Tang H
    J Viral Hepat; 2013 Apr; 20 Suppl 1():40-5. PubMed ID: 23458523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir.
    Son CY; Ryu HJ; Lee JM; Ahn SH; Kim DY; Lee MH; Han KH; Chon CY; Park JY
    Liver Int; 2012 Aug; 32(7):1179-85. PubMed ID: 22452737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis.
    Ye XG; Su QM
    World J Gastroenterol; 2013 Oct; 19(39):6665-78. PubMed ID: 24151397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH; Wang JH; Lu SN; Hu TH; Hung CH; Chang MH; Changchien CS; Lee CM
    Antivir Ther; 2012; 17(4):701-9. PubMed ID: 22358132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telbivudine versus lamivudine and entecavir for treatment-naïve decompensated hepatitis B virus-related cirrhosis.
    Yue-Meng W; Li YH; Wu HM; Yang J; Xu Y; Yang LH; Yang JH
    Clin Exp Med; 2017 May; 17(2):233-241. PubMed ID: 27094312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.